Adaptive Biotechnologies (NASDAQ:ADPT) Insider Susan Bobulsky Sells 1,299 Shares of Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Susan Bobulsky sold 1,299 shares of the firm’s stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $24.00, for a total transaction of $31,176.00. Following the completion of the transaction, the insider directly owned 399,989 shares of the company’s stock, valued at approximately $9,599,736. This trade represents a 0.32% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Susan Bobulsky also recently made the following trade(s):

• On Wednesday, July 1st, Susan Bobulsky sold 487 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $22.00, for a total transaction of $10,714.00.
• On Thursday, June 11th, Susan Bobulsky sold 5,000 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $19.00, for a total transaction of $95,000.00.
• On Thursday, June 4th, Susan Bobulsky sold 11,000 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $18.00, for a total transaction of $198,000.00.

Adaptive Biotechnologies Price Performance

Shares of NASDAQ ADPT opened at $23.11 on Tuesday. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.79 and a quick ratio of 4.68. The business has a 50-day moving average of $19.61 and a 200-day moving average of $16.68. The stock has a market capitalization of $3.70 billion, a price-to-earnings ratio of -56.37 and a beta of 2.08. Adaptive Biotechnologies Corporation has a fifty-two week low of $10.19 and a fifty-two week high of $24.57.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings data on Tuesday, July 28th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.12). The firm had revenue of $71.55 million for the quarter, compared to the consensus estimate of $65.44 million. Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.Adaptive Biotechnologies’s quarterly revenue was up 21.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.17) earnings per share. As a group, sell-side analysts predict that Adaptive Biotechnologies Corporation will post -0.43 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on ADPT. Morgan Stanley raised their price target on Adaptive Biotechnologies from $20.00 to $22.00 and gave the company an “equal weight” rating in a report on Thursday, July 30th. Guggenheim increased their target price on Adaptive Biotechnologies from $22.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday. JPMorgan Chase & Co. lowered their target price on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. BTIG Research lifted their price target on Adaptive Biotechnologies from $24.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Finally, TD Cowen upped their price target on shares of Adaptive Biotechnologies from $25.00 to $28.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Adaptive Biotechnologies currently has an average rating of “Moderate Buy” and a consensus price target of $23.33.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Adaptive Biotechnologies in the 4th quarter valued at $28,000. EverSource Wealth Advisors LLC lifted its stake in shares of Adaptive Biotechnologies by 197.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after acquiring an additional 1,565 shares during the period. Assetmark Inc. boosted its holdings in Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after acquiring an additional 2,708 shares during the last quarter. T. Rowe Price Investment Management Inc. bought a new position in Adaptive Biotechnologies in the fourth quarter valued at about $51,000. Finally, Strive Financial Group LLC bought a new position in Adaptive Biotechnologies in the fourth quarter valued at about $52,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.